(4-溴苯基)(噻唑-2-基)甲醇 | 356552-30-2

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-溴苯基)(噻唑-2-基)甲醇
• 英文名称: (4-bromophenyl)-thiazole-2-yl-methanol
• 英文别名: (4-bromophenyl)thiazol-2-ylmethanol；(4-Bromophenyl)(thiazol-2-yl)methanol；(4-bromophenyl)-(1,3-thiazol-2-yl)methanol
• CAS: 356552-30-2
• 化学式: C₁₀H₈BrNOS
• 分子量: 270.15
• InChiKey: WJQRNBMHNPHGCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-溴苯基)(噻唑-2-基)甲醇 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以80%的产率得到(4-bromophenyl)(thiazol-2-yl)methanone
  参考文献：
  名称：

  [EN] NEW TRICYCLIC ANGIOTENSIN II AGONISTS
  [FR] NOUVEAUX AGONISTES TRICYCLIQUES DE L'ANGIOTENSINE II

  摘要：

  提供了式(I)的化合物，其中虚线，X1，X2，X3，X4，A，Y1，Y2，Y3，Y4，Z1，Z2，R2和R3的含义如描述中所给，并且其药学上可接受的盐，这些化合物可用作AT2受体的选择性激动剂，因此，特别适用于治疗包括消化不良、肠易激综合征和多器官功能衰竭在内的胃肠道疾病以及心血管疾病。

  公开号：

  WO2004046141A1
• 作为产物：
  描述：

  2-(三甲基硅基)噻唑 、 对溴苯甲醛 以0%的产率得到
  参考文献：
  名称：

  Dondoni Alessandro, Douglas Alan W., Shinkai Ichiro, J. Org. Chem., 58 (1993) N 11, S 3196-3200

  摘要：

  DOI：

文献信息

• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASES A CYSTEINE DE TYPE CATHEPSINE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004022526A1

  公开（公告）日：2004-03-18

  This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. They have the following structure: Formula (I).

  这项发明涉及一类化合物，这些化合物是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物可用于治疗需要抑制骨吸收的疾病，如骨质疏松症。它们具有以下结构：化学式（I）。
• Cathepsin cysteine protease inhibitors
  申请人：Boyd Michael

  公开号：US20060122268A1

  公开（公告）日：2006-06-08

  This invention relates to class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis. They have the following structure: Formula (I).

  本发明涉及一类化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普西林K、L、S和B的抑制剂。这些化合物对于治疗需要抑制骨吸收的疾病，如骨质疏松症，非常有用。它们具有以下结构：式（I）。
• Selective angiotensin II AT2 receptor agonists with reduced CYP 450 inhibition
  作者：A.K. Mahalingam、Yiqian Wan、A.M.S. Murugaiah、Charlotta Wallinder、Xiongyu Wu、Bianca Plouffe、Milad Botros、Fred Nyberg、Anders Hallberg、Nicole Gallo-Payet

  DOI：10.1016/j.bmc.2010.03.064

  日期：2010.6.15

  Structural alterations to the benzylic position of the first drug-like selective angiotensin II AT(2) receptor agonist (1) have been performed, with the emphasis to reduce the CYP 450 inhibitory property of the initial structure. The imidazole moiety, responsible for the CYP 450 inhibitory effect in 1, was replaced with various heterocycles. In addition, the modes of attachment of the heterocycles, that is, carbon versus nitrogen attachment, and introduction of carbonyl functionalities to the benzylic position have been evaluated. In all the three series, AT(2) receptor ligands with affinity in the lower nanomolar range were identified. None of the analogues, regardless of the substituents, exhibited any affinity for the AT(1) receptor. Compounds with substantially reduced inhibition of the CYP 450 enzymes were obtained. Among them the compound 60 was found to induce neurite elongation in NG 108-15 cells and served as potent AT(2) selective agonist. (C) 2010 Elsevier Ltd. All rights reserved.
• Rapid Mo(CO)6 catalysed one-pot deoxygenation of heterocyclic halo-benzyl alcohols with Lawesson’s reagent
  作者：Xiongyu Wu、A.K. Mahalingam、Mathias Alterman

  DOI：10.1016/j.tetlet.2005.01.012

  日期：2005.2

  A fast and efficient microwave promoted one-pot method for deoxygenation of heterocyclic halo-benzyl alcohols has been developed. The method does not cause dehalogenation of the substrates and provides the deoxygenated products in high yield after only 30 min. (C) 2005 Elsevier Ltd. All rights reserved.
• CATHEPSIN CYSTEINE PROTEASE INHIBITORS
  申请人：MERCK FROSST CANADA INC.

  公开号：EP1537074A1

  公开（公告）日：2005-06-08